Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Health Technology Assessment (Winchester, England)|May 30, 2006
A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1M Connock, A Juarez-Garcia, E Frew, et al.
Nature Biotechnology|May 12, 2009
Small but tenacious: South Africa's health biotech sectorSara Al-Bader, Sarah E Frew, Insiya Essajee, et al.
Clinical and Experimental Dermatology|May 1, 1990
Psittacosis presenting with erythema-marginatum-like lesions--a case report and a historical reviewS T Green, N W Hamlet, L Willocks, et al.
Blood|September 20, 2002
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitorsPanagiotis D Kottaridis, Rosemary E Gale, Stephen E Langabeer, et al.
Health Technology Assessment (Winchester, England)|February 7, 2007
Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluationY Adi, A Juarez-Garcia, D Wang, et al.
Health Technology Assessment (Winchester, England)|March 21, 2006
The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic reviewM Connock, E Frew, B-W Evans, et al.
Science (New York, N.Y.)|August 18, 2001
An essential role for BAFF in the normal development of B cells through a BCMA-independent pathwayB Schiemann, J L Gommerman, K Vora, et al.
Health Technology Assessment (Winchester, England)|December 13, 2005
The effectiveness and cost-effectiveness of parent training/education programmes for the treatment of conduct disorder, including oppositional defiant disorder, in childrenJ Dretzke, E Frew, C Davenport, et al.
Blood|December 7, 2002
CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplicationDavid T Bowen, Marion E Frew, Sara Rollinson, et al.
Health Technology Assessment (Winchester, England)|June 27, 2006
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic reviewM Connock, A Burls, E Frew, et al.
Pageof 5